Mechanistically, IR-546 activated GSK-3β Ser9 phosphorylation, which suppressed β-catenin and its downstream proteins in vitro and in vivo, thereby inhibiting melanoma growth through suppression of the AKT/GSK-3β/β-catenin pathway. Here, AKT1 is linked to melanoma.